Elicera Therapeutics AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Other Revenue	13.7	7.13	11.23	1.28	0	-
Revenue	13.7	7.13	11.23	1.28	0	-
Revenue Growth (YoY)	219.62%	-36.52%	777.23%	217987.39%	-	-
Gross Profit	13.7	7.13	11.23	1.28	0	-
Selling, General & Admin	27.42	24	28.31	20.63	13.11	2.82
Operating Expenses	27.42	24.01	28.33	20.64	13.12	2.83
Operating Income	-13.73	-16.88	-17.1	-19.36	-13.12	-2.83
Interest Expense	-0.01	-0.05	-0.08	-0.13	-0	-
Interest & Investment Income	0.69	0.83	0.77	0.05	-	-
Other Non Operating Income (Expenses)	0	0	-	-	0	-
EBT Excluding Unusual Items	-13.04	-16.11	-16.4	-19.44	-13.12	-2.83
Gain (Loss) on Sale of Investments	-	-	-	-	-	0.01
Pretax Income	-13.04	-16.11	-16.4	-19.44	-13.12	-2.82
Net Income	-13.04	-16.11	-16.4	-19.44	-13.12	-2.82
Net Income to Common	-13.04	-16.11	-16.4	-19.44	-13.12	-2.82
Shares Outstanding (Basic)	42	32	20	20	16	12
Shares Outstanding (Diluted)	42	32	20	20	16	12
Shares Change (YoY)	52.64%	59.89%	-0.40%	23.97%	32.98%	-
EPS (Basic)	-0.31	-0.51	-0.83	-0.98	-0.82	-0.23
EPS (Diluted)	-0.31	-0.51	-0.83	-0.98	-0.82	-0.23
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-100.23%	-236.86%	-152.24%	-1512.51%	-2234986.20%	-
Profit Margin	-95.24%	-226.01%	-146.02%	-1518.44%	-2235169.17%	-
EBITDA	-13.72	-16.87	-17.08	-19.35	-13.11	-2.82
EBITDA Margin	-100.14%	-236.70%	-152.13%	-	-	-
D&A For EBITDA	0.01	0.01	0.01	0.01	0.01	0.01
EBIT	-13.73	-16.88	-17.1	-19.36	-13.12	-2.83
EBIT Margin	-100.23%	-236.86%	-152.24%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.